SEC Form 4 · accession 0000899243-18-001348
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Tyler Dylan-Hyde
Officer — Chief Legal Officer
Period of report
Jan 16, 2018
Accepted (ET)
Jan 18, 2018 · 5:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF2 | Jan 16, 2018 | S | 45,000 | $28.00 | D | 25,204 | D | |
| Common Shares | Jan 16, 2018 | M | 1,110 | $12.57 | A | 26,314 | D | |
| Common Shares | Jan 16, 2018 | S | 1,110 | $28.24 | D | 25,204 | D | |
| Common Shares | Jan 16, 2018 | M | 19,890 | $12.57 | A | 45,094 | D | |
| Common SharesF3 | Jan 16, 2018 | S | 19,890 | $28.10 | D | 25,204 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $12.57 | Jan 16, 2018 | M | 1,110 | D | — | Jul 15, 2026 | Common Shares | 1,110 | 36,663 | D |
| Stock Option (Right to Buy)F5 | $12.57 | Jan 16, 2018 | M | 19,890 | D | — | Jul 15, 2026 | Common Shares | 19,890 | 5,237 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $28.75, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.85 to $28.75, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F4This option was granted on July 15, 2016 with respect to 53,333 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016.
- F5This performance-based option was granted on July 15, 2016 with respect to 26,667 Common Shares with 100% of the shares vesting within 12 months of the date of grant, subject to the satisfaction of mutually agreed upon performance metrics.